UB-312 represents a promising avenue in Parkinson's disease (PD) treatment by focusing on pathological forms of alpha-synuclein (aSyn), a key protein associated with the progression of synucleinopathies. Unlike conventional approaches, UB-312 aims to elicit antibodies that specifically recognize and neutralize these harmful forms of aSyn, potentially halting or slowing the neurodegenerative processes underlying PD
The Phase I trial revealed that UB-312 was immunogenic in both healthy volunteers and Parkinson's disease patients. This suggests that the investigational active immunotherapy has the ability to stimulate the immune system to produce an antibody response...
